



LY2562175

Catalog No: tcsc0033341

Available Sizes	
Size: 1mg	
Size: 5mg	
Size: 10mg	
Size: 25mg	
Size: 50mg	
Specifications	
CAS No: 1103500-20-4	
Formula: C ₂₈ H ₂₇ Cl ₂ N ₃ O ₄	
Pathway: Metabolic Enzyme/Protease	
Target: FXR	
Purity / Grade: >98%	
Solubility: 10 mM in DMSO	
Starna Instruction	

Storage Instruction:

Dry, Keep in dark; at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years); Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping.





Observed Molecular Weight:

540.44

Product Description

LY2562175 is a potent and selective **FXR** agonist with an $\mathbf{EC_{50}}$ of 193 nM.

IC50 & Target: EC50: 193 nM (FXR)

In Vitro: LY2562175 promotes transcriptional activation of human FXR in a cell-based co-transfection assay with an EC $_{50}$ of 193 nM. LY2562175 promotes recruitment of a peptide from the nuclear receptor interaction domain of the coactivator SRC-1 with a relative EC $_{50}$ of 121 nM and 93.5% efficacy as compare to GW4064^[1].

In Vivo: LY2562175 causes a dose-dependent decrease in serum cholesterol and serum triglycerides. At a dose of 10 mg/kg, the decrease in cholesterol with LY2562175 is 80% below vehicle-treated animals, and the decrease in serum triglycerides is 76% from control group. The ED₅₀ for serum cholesterol is determined to be 2 and 3.4 mg/kg for serum triglycerides. Treatment of female ZDF rats with LY2562175 results in a dose dependent lowering of plasma triglycerides in the fasted and nonfasted states. When administered as a fixed dose combination with rosiglitazone, LY2562175 further lowers fasted and nonfasted plasma triglycerides. FPLC fractionation of the lipoproteins reveals that LY2562175 treatment results in a reduction in vLDL-C and a dramatic increase in HDL-c in this animal model^[1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!